In the case of a 62-year-old woman with metastatic non–small cell lung cancer, answer question of what you would do in terms ...
Puneeth Indurlal, MD, MS, discusses the implications of assessing for patients' health-related social needs during the course of cancer treatment at the 2024 ASCO Annual Meeting.
The FDA has granted a fast track designation to AGuIX, a gadolinium-based nanodrug currently under evaluation for treating ...
Zolbetuximab could become the first CLDN18.2-targeted therapy approved for this patient population in the US. The FDA has ...
In an interview with Targeted Oncology, Paolo Ghia, MD, PhD, discussed the 5-year results from the CAPTIVATE study in chronic ...
Vikram Narayan, MD, discusses the significance of the 5-year overall survival and cystectomy-free survival rates of ...
Halle Moore, MD, discusses key takeaways from a study on young patients with breast cancer carrying BRCA mutations presented ...
The combination of camrelizumab and rivoceranib significantly improved survival rates in patients with unresectable liver ...
The FDA approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi) for the ...
Dr. Bose discusses the REALISE trial and its implications for ruxolitinib dosing strategy, particularly in terms of safety ...
Dr. Bose discusses the impact of ruxolitinib on the overall survival of patients with MF and briefly reviews the COMFORT I ...
During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed long-term outcomes of the TIVO-3 trial in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results